AUTLHIGH SIGNALFINANCIAL10-K

AUTL experienced substantial deterioration in its financial position with stockholders' equity declining by more than half and cash reserves being significantly depleted during the period.

The company's balance sheet shows concerning capital consumption patterns, with stockholders' equity falling to $178.1M from $427.3M and cash declining to $104.1M from $227.4M. This substantial financial deterioration, combined with worsening operating cash burn, raises questions about the company's ability to sustain operations and fund its commercial launch activities without additional capital raising.

Comparing 2026-03-27 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

AUTL's financial position weakened materially across key metrics, with stockholders' equity and cash reserves both declining by more than half. Operating cash burn increased meaningfully to $284M while R&D expenses modestly decreased and SG&A expenses grew 30%, likely reflecting commercial launch investments. The overall financial picture signals significant capital consumption that may require near-term financing to support ongoing operations and the AUCATZYL commercial rollout.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-58.3%
$427.3M→$178.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-54.2%
$227.4M→$104.1M

Cash declined 54.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
-37.5%
-$206.3M→-$283.6M

Operating cash flow fell 37.5% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Assets
Balance Sheet
-34%
$660.9M→$435.9M

Current assets declined 34% — monitor working capital adequacy and short-term liquidity.

SG&A Expense
P&L
+30.5%
$101.1M→$131.9M

SG&A up 30.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Net Income
P&L
-30.3%
-$220.7M→-$287.5M

Net income declined 30.3% — review whether driven by operations, interest costs, or non-recurring items.

Total Assets
Balance Sheet
-24.7%
$782.7M→$589.1M

Total assets contracted 24.7% — asset sales, write-downs, or balance sheet optimization underway.

Current Liabilities
Balance Sheet
+20.9%
$60.7M→$73.4M

Current liabilities rose 20.9% — increased short-term obligations, watch current ratio.

Total Liabilities
Balance Sheet
+15.6%
$355.4M→$410.9M

Liabilities increased 15.6% — monitor debt-to-equity ratio and interest coverage.

R&D Expense
P&L
-15%
$138.4M→$117.7M

R&D spending cut 15% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-20
ADDED
As of March 26, 2026, there were 266,143,286 of the registrant s ordinary shares (including in the form of ADSs), with a nominal value of $0.000042 per share, outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 104 Item 7A.
Forward-looking statements include statements about: the therapeutic potential and expected clinical benefits of AUCATZYL/obe-cel (obecabtagene autoleucel) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia ( r/r B-ALL ); our ability to generate revenues from AUCATZYL, which is dependent upon maintaining significant market acceptance among physicians, patients and healthcare payors; our ability to maintain regulatory approval of AUCATZYL in the US, European Union ( EU ) and United Kingdom ( U.K.
You are urged to carefully review the disclosures we make concerning these risks and other factors that may affect our business and operating results in this Annual Report.
Post approval regulatory burden has increased, and may continue to increase, as regulators are increasingly granting approvals contingent on the performance of costly post marketing clinical trials, sometimes focused on long term data.
These requirements make the maintenance of regulatory approvals and label expansions for our products increasingly expensive, and further heighten the risk of recalls, product withdrawals, changes to product specifications, loss of market share, and loss of revenue and profitability.
Business Business Overview We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune diseases.
Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate target cells.
In November 2024, the United States Food and Drug Administration (the FDA ) approved our biologics license application ( BLA ) for the marketing of AUCATZYL (obecabtagene autoleucel, also known as obe-cel) in the United States for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia ( r/r B-ALL ).
The commercial launch and first sale of AUCATZYL in the United States occurred in January 2025.
REMOVED
As of March 19, 2025, there were 266,128,900 of the registrant s ordinary shares (including in the form of ADSs), with a nominal value of $0.000042 per share, outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 101 Item 7A.
You are urged to carefully review the disclosures we make concerning these risks and other factors that may affect our business and operating results in this Annual Report on Form 10-K.
Business Business Overview We are an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases.
Food and Drug Administration, or FDA, granted marketing approval for our first approved commercial product, AUCATZYL/obe-cel (obecabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, or r/r B-ALL.
We commercially launched AUCATZYL in the United States in January 2025, and we plan to initiate sales of AUCATZYL/obe-cel in the European Union, or EU, and the United Kingdom, or UK, once regulatory approval is received.
Marketing authorization submissions for AUCATZYL/obe-cel were accepted by the European Medicines Agency, or EMA, in April 2024 and the U.K.
Medicines and Healthcare products Regulatory Agency, or MHRA, in August 2024, and we expect to receive notification of approval status from these authorities in the second half of 2025.
AUCATZYL is a CD19-targeting programmed T cell investigational therapy with a CD19 binder designed to improve the efficacy and safety profile, as compared to other CD19 CAR T chimeric antigen receptor T cell, or CAR T, therapies.
If we receive approval to commercialize AUCATZYL outside of the United States, we intend for the Nucleus to meet the global supply demands of AUCATZYL, with Cardinal Health serving as our commercial distribution partner in the United States.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →